Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pan-cancer landscape of CD274 (PD-L1) copy number changes in 244 584 patient samples and the correlation with PD-L1 protein expression.

Journal for immunotherapy of cancer - 1 May 2021

Huang Richard S P, Murugesan Karthikeyan, Montesion Meagan, Pavlick Dean C, Mata Douglas A, Hiemenz Matthew C, Decker Brennan, Frampton Garrett, Albacker Lee A, Ross Jeffrey S

Abstract excerpt

INTRODUCTION: Several studies have shown clinical outcomes data that support the use of CD274 (PD-L1) copy-number (CN) gains and/or losses as a biomarker for immune checkpoint inhibitor (ICPI). Here, we present the landscape of CD274 CN changes across a large cohort of solid tumor cases and correlate these with PD-L1 protein expression by immunohistochemistry. METHODS: We analyzed all cases that underwent...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to B7-H1 Antigen
Share to Clinical Decision-Making

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Copy Number Variations

Share to Gene Dosage

Share to Immune Checkpoint Inhibitors

Share to Microsatellite Instability

Share to Molecular Diagnostic Techniques

Share to Predictive Value of Tests

Source

Open in PubMed Open full text

Identifiers

PMID: 33972391
DOI: 10.1136/jitc-2021-002680
PMCID: PMC8112409

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pan-cancer landscape of CD274 (PD-L1) copy number changes in 244 584 patient samples and the correlation with PD-L1 protein expression.PMID 33972391Read ↗

Pan-cancer analysis of copy number changes in programmed death-ligand 1 (PD-L1, CD274) - associations with gene expression, mutational load, and survival.Semantic proximity Read ↗

Pan-cancer analysis of CD274 (PD-L1) mutations in 314,631 patient samples and subset correlation with PD-L1 protein expression.Semantic proximity Read ↗

A pan-cancer analysis of PD-L1 immunohistochemistry and gene amplification, tumor mutation burden and microsatellite instability in 48,782 cases.Semantic proximity Read ↗

A comprehensive pan-cancer analysis of CD274 gene amplification, tumor mutation burden, microsatellite instability, and PD-L1 expression in Chinese cancer patientsSemantic proximity Read ↗

PD-L1 expression and tumor mutational burden are independent biomarkers in most cancersSemantic proximity Read ↗

Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors.Semantic proximity Read ↗

Gene code CD274/PD-L1 : from molecular basis toward cancer immunotherapySemantic proximity Read ↗

High tumor mutational burden predicts favorable response to anti-PD-(L)1 therapy in patients with solid tumor: a real-world pan-tumor analysis.Semantic proximity Read ↗

Immune-Omics Networks of CD27, PD1, and PDL1 in Non-Small Cell Lung CancerSemantic proximity Read ↗

Chromosome 9p copy number gains involving PD-L1 are associated with a specific proliferation and immune-modulating gene expression program active across major cancer typesSemantic proximity Read ↗

Large-Scale Meta-Analysis of Potential Biomarkers for Treatment Response to Anti-PD-1/PD-L1 Immune Checkpoint InhibitorsSemantic proximity Read ↗

Intrapatient variation in PD-L1 expression and tumor mutational burden and the impact on outcomes to immune checkpoint inhibitor therapy in patients with non-small-cell lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.